-
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in non-human primates
May 13, 2020
… Parkinson's disease (PD). Much evidence, accumulated from multiple experimental models, has suggested that α-syn plays … supporting the true multifactorial nature of PD, as multiple causes can induce a similar outcome regarding …
-
Paul Davies, PhD
… more recently motor neuron disease. He is also involved in multiple technology development projects in the areas of … ongoing in the Unit. Dr. Davies’ team also works on multiple industry projects and technology development. …
-
Farren Basil Shaw Briggs, PhD
… in genetic epidemiology. Dr. Briggs is a former National Multiple Sclerosis Society postdoctoral fellow. His research has focused on multiple sclerosis (MS), another complex neurodegenerative …
-
G. Sridhar Prasad, PhD
… Inc., where he was lead crystallographer and core member of multiple drug discovery programs, including schizophrenia … in building and implementing fragment-based technologies in multiple organizations including Merck and Metabasis. He is …
-
Discovery of LRRK2 Target Engagement Ligands to be Used in Imaging Studies
… discovery of a neuroprotective agent for treatment of PD. Multiple mutations within the LRRK2 gene are associated with … is desirable. Project Description: We have identified multiple chemical series that inhibit LRRK2 kinase activity … imaging agent. The first year of the program will identify multiple lead compounds for radio-labeling. … LRRK2 … …
-
Anna Quattropani, PhD
… optimizing drug-like small molecules with CNS exposure for multiple sclerosis and Alzheimer’s disease therapeutics. She … for progressive supranuclear palsy (O-GlcNAcase inhibitor), multiple sclerosis and an oxytocin receptor antagonist that …